Display Settings:

Format

Send to:

Choose Destination
J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):607-14. doi: 10.1097/QAI.0b013e3181648e16.

Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children.

Collaborators (254)

Paul ME, Jackson C, Minglana F, Rathore MH, Mirza A, Champion K, Mendoza A, Yogev R, Chadwick E, Febo IL, Lugo L, Santos R, Heyer I, Purswani M, Baksi S, Stuard E, Dummit M, Acevedo M, Gonzalez M, Fabregas L, Texidor ME, Scott GB, Mitchell CD, Florez C, Gamber J, Bardeguez A, Dieudonne A, Bettica L, Johnson J, Silio M, Alchediak T, Boe C, Cowie M, Van Dyke R, Spector SA, Viani RM, Caffery M, Norris K, Rana S, Finke H, Yu P, Roa J, Donovan M, Serrano R, Burey M, Auguste R, Chen J, Foster J, Stechenberg BW, Fisher DJ, Johnston AM, Toye M, Homans J, Neely M, Spencer LS, Burchett S, Karthas N, Moore E, Cromer C, Gaur A, Knapp K, Patel N, Donohoe M, Minter M, Hastings T, Akleh S, Borkowsky W, Handelsman E, Moallem HJ, Swindell DM, Kaye JM, Higgins A, Foca M, LaRussa P, Gershon A, Douglas SD, Rutstein RM, Vincent CA, Coburn PC, Petru A, Courville T, Eng K, Gold K, Wara DW, Tilton N, Muscat M, McFarland E, Salbenblatt C, Hutton N, Griffith B, Joyner M, Kiefner C, Acker M, Melvin AJ, Mohan KM, Phelps S, Bamji M, Pathak I, Manwani S, Patel E, Dobbins D, Wimbley D, Perron T, Spiegel H, Luzuriaga K, Moriarty R, Pass R, Crain M, Watson D, Farley J, Klipner K, Hilyard C, Bonagura VR, Schuval SJ, Colter C, Campbell L, Pelton SI, Cooper ER, Kay L, Regan AM, Rich KC, Hayani K, Bicchinella M, Camacho J, Nachman S, Ferraro D, Perillo J, Kelly M, Puga AM, Talero G, Blood J, Juliano S, Mathison C, Whitfield K, Wiley F, Donnelly M, Champion S, Frere M, DiGrado M, Abrams EJ, McAuley JB, Boyer KM, Haak M, Martinez J, Mancao M, Estrada B, Salazar JC, Karas G, Belhorn T, Eddleman J, Pitkin B, Figueroa W, Reyes E, Weiner LB, Contello KA, Holz WA, Famiglietti MJ, Winborn A, Wendel G, Lawrence R, Lew J, Delany C, Duff C, Fernandez AD, Hughes PA, Wade N, Adams ME, Gomez D, Sinanan J, Piatt JP, Foti J, Clarke-Steffen L, Sleasman J, Delaney C, Foshee S, Mani CS, Murray DL, White C, Andiman WA, Hurst L, de Jesus J, Schroeder D, Weinberg GA, Gigliotti F, Murante B, Laverty S, Hutchcon N, Townley A, Nesheim S, Dennis R, Emmanuel P, Lujan-Zilberman J, Graisberry C, Moore S, Fisher RG, Cunnion KM, Rubio TT, Sandifer D, Johnson GM, Gay H, Sadler S, Keller MA, Redjal N, Wettgen S, Sullivan S, Johnson D, Church J, Dunaway T, Salata C, Marks S, Elkins K, Batra J, Deveikis A, Gaur S, Whitley-Williams P, Malhotra A, Cerracchio L, Dolan M, D'Agostino J, Posada R, Mani C, Cobb S, Lavoie SR, Smith TY, Feingold A, Burrows-Clark S, Mrus J, Beiting R, Brady M, Hunkler J, Koranyi K, Albritton W, Warford R, Arpadi S, Gershon A, Miller P, Rubinstein A, Krienik G, Kovacs A, Operskalski E, Wara D, Kamrin A, Farrales S, Tilton N, Muscat M, Johan-Liang R, O'Keefe K, McGann KA, Pickering L, Storch GA, Pahwa S, Rodriquez L, Lewis P, Croteau R.

Author information

  • 1Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA 02115, USA. ktassiop@hsph.harvard.edu

Abstract

CONTEXT:

Antiretroviral therapy has been associated with hypercholesterolemia in HIV-infected children. Few longitudinal studies have been conducted to examine this association, however.

OBJECTIVE:

To evaluate the incidence of and risk factors for development of hypercholesterolemia in a large pediatric study.

DESIGN:

Prospective cohort study (Pediatric AIDS Clinical Trials Group 219C).

PARTICIPANTS:

A total of 2122 perinatally HIV-infected children free of hypercholesterolemia at entry.

OUTCOME:

Development of hypercholesterolemia (total cholesterol >or=220 mg/dL at 2 consecutive visits). Cox proportional hazards models were used to evaluate risk factors.

RESULTS:

Thirteen percent of children had hypercholesterolemia at entry, and an additional 13% developed hypercholesterolemia during follow-up for an incidence rate of 3.4 cases per 100 person-years (95% confidence interval [CI]: 3.0 to 3.9). After adjustment for age, boosted protease inhibitor (PI) use (hazard ratio [HR] = 13.9, 95% CI: 6.73 to 28.6), nonboosted PI use (HR = 8.65, 95% CI: 4.19 to 17.9), and nonnucleoside reverse transcriptase inhibitor use (HR = 1.33, 95% CI: 1.04 to 1.71) were associated with increased risk of hypercholesterolemia, and higher viral load was protective (>50,000 vs. <or=400 copies/mL; HR = 0.59, 95% CI: 0.39 to 0.90). Self-reported adherent subjects had higher risk.

CONCLUSIONS:

PIs were significant risk factors for hypercholesterolemia. Higher viral load was protective and may reflect nonadherence. Further follow-up is critical to evaluate long-term consequences of chronic PI exposure and hypercholesterolemia.

PMID:
18209684
[PubMed - indexed for MEDLINE]
PMCID:
PMC3089963
Free PMC Article

Images from this publication.See all images (1)Free text

FIGURE 1
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Lippincott Williams & Wilkins Icon for PubMed Central
    Loading ...
    Write to the Help Desk